Sangamo Biosciences CEO Alexander Macrae's 2019 pay slips 3% to $4M
Sangamo Biosciences reports 2019 executive compensation
By ExecPay News
Published: April 1, 2020
Sangamo Biosciences reported fiscal year 2019 executive compensation information on April 1, 2020.
In 2019, seven executives at Sangamo Biosciences received on average a compensation package of $2.1M, a 22% decrease compared to previous year.
Average pay of disclosed executives at Sangamo Biosciences
Alexander D. Macrae, Chief Executive Officer, received $4M in total, which decreased by 3% compared to 2018. 57% of Macrae's compensation, or $2.3M, was in option awards. Macrae also received $437K in non-equity incentive plan, $662K in salary, $571K in stock awards, as well as $42K in other compensation.
For fiscal year 2019, the median employee pay was $159,900 at Sangamo Biosciences. Therefore, the ratio of Alexander D. Macrae's pay to the median employee pay was 25 to one.
Sung H. Lee, Chief Financial Officer, received a compensation package of $2.5M. 69% of the compensation package, or $1.8M, was in option awards.
Adrian Woolfson, Executive Vice President, Research and Development, earned $2.3M in 2019.
Gary H. Loeb, General Counsel, received $2M in 2019.
Stéphane Boissel, Chief Financial Officer, earned $1.5M in 2019, a 43% decrease compared to previous year.
R. Andrew Ramelmeier, Executive Vice President, Technical Operations, received $1.1M in 2019.
Kathy Y. Yi, Chief Financial Officer, earned $1.1M in 2019, a 16% decrease compared to previous year.
Related executives
Alexander Macrae
Sangamo Biosciences
Chief Executive Officer
Sung Lee
Sangamo Biosciences
Chief Financial Officer
Stéphane Boissel
Sangamo Biosciences
Former Executive Vice President, Corporate Strategy
Adrian Woolfson
Sangamo Biosciences
Executive Vice President, Research and Development
Gary Loeb
Sangamo Biosciences
General Counsel
R Ramelmeier
Sangamo Biosciences
Executive Vice President, Technical Operations
Kathy Yi
Sangamo Biosciences
Chief Financial Officer
You may also like
Source: SEC filing on April 1, 2020.